GSK Earnings & Forecasts

GSK (GSK) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Jul 28, 2026	$1.35	$1.27	6.61 %
Q1	Apr 29, 2026	$1.25	$1.17	6.84 %
Q4	Feb 4, 2026	$0.68	$0.64	6.25 %
Q3	Oct 29, 2025	$1.48	$1.26	17.8 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Jul 28, 2026	$11.28B	$10.79B	4.54 %
Q1	Apr 29, 2026	$10.30B	$10.19B	1.07 %
Q4	Feb 4, 2026	$11.46B	$11.19B	2.41 %
Q3	Oct 29, 2025	$11.53B	$11.16B	3.29 %

GSK Guidance

GSK (GSK) は、7 28, 2026 年に fiscal year 2026 のガイダンスを最後に発表しました。同社は 1 株当たり利益を $4.9 - $5 の範囲と予想し、コンセンサス EPS 予想は $4.79 でした。GSK も、この期間の売上高を $44.75B - $44.75B の範囲と予想しました。

以前のガイダンスと比較すると、GSKはEPS見通しを以前の範囲である維持から$4.9 - $5に引き上げました。売上高については、同社は売上高予測を以前の範囲である維持から$44.75B - $44.75Bに引き上げました。

GSKは、16から11 2, 2022の間に7 28, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 6 times and lowered it 5 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$1.27	$1.17	$0.64	$1.26
Actual	$1.35	$1.25	$0.68	$1.48
Surprise	+6.61%	+6.84%	+6.25%	+17.8%
Revenue
Estimate	$10.79B	$10.19B	$11.19B	$11.16B
Actual	$11.28B	$10.30B	$11.46B	$11.53B
Surprise	+4.54%	+1.07%	+2.41%	+3.29%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$1.45	$0.76	$1.27	$1.35
Revenue
Consensus	$11.86B	$12.13B	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.

Vandana Singh

PRO
GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

GSK (NYSE:GSK) FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

Benzinga Newsdesk

PRO
GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est

GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.690 billion estimate.

Benzinga Newsdesk

GSK PLC